Posted by Michael Wonder on 09 Feb 2023
Lorlatinib for the first-line treatment of patients with ALK positive advanced non-small-cell lung cancer
9 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of lorlatinib in the NHS in England.
Lorlatinib is not recommended for the treatment of adults with anaplastic lymphoma kinase (ALK) positive advanced non-small-cell lung cancer in adults who have not had an ALK inhibitor.
